drugset / Trial / NCT00403455

Monoamine Transporters Genotypes: Risk of PTSD and Related Comorbidities

NCT00403455

Phase 3 Completed 38 enrolled VA Office of Research and Development
NaSingle-groupOpen-labelTreatment

Summary

Dr. Wang's merit review is aimed at providing a better understanding of the relationship between SLC6A3/SLC6A4 and the mental health of veterans exposed to high levels of combat stress, specifically focusing on PTSD symptoms, related co-morbidities, treatment outcomes and seeks new approaches to therapy for our Veteran population.

Timeline

Start
2006-10
Primary completion
2011-07
Completion
2011-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Paroxetine Small molecule